AbelZeta Pharma
PrivateLast Round
Series A
Sep 30, 2021
Total Funding Raised
$120M
Company Overview
AbelZeta Pharma is a biopharmaceutical company that focuses on developing innovative and proprietary cell-based therapeutic products to treat hematological malignancies, solid tumors, and inflammatory and immunological diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AbelZeta Pharma Comparables
Compare AbelZeta Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PersonGen BioTherapeutics | 84% | |
| Oricell Therapeutics | 84% | |
| Shanghai YaKe Biotechnology Co., Ltd. | 82% |
AbelZeta Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 30, 2021 |
AbelZeta Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GIC Private Limited | Series A |
| CICC Capital | Series A |
| Yunfeng Capital | Series A |
| HongShan Capital Group (HSG) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 15, 2024
Monthly visitors grew 33% MoM, reaching 2.4K.
- Oct 30, 2024
Monthly visitors increased 80% MoM.
Recent news
Latest coverage and updates
- sells_assets_toJul 23, 2026
AbelZeta Inc. sold assets to AstraZeneca Pharmaceutical Co., Ltd. on Jan 1st '26.
- is_developingJul 23, 2026
AbelZeta Inc. is developing C-CAR031 on Dec 1st '23.
- is_developingJul 20, 2026
AbelZeta Inc. is developing dual-target CAR-T technology on Jul 20th '26.
- recognized_asJul 20, 2026
AbelZeta Inc. recognized as EMA PRIME designation for C-CAR168 in Lupus Nephritis and Systemic Lupus Erythematosus. on Jul 20th '26.
AbelZeta Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AbelZeta Pharma's valuation, stock price, and market status.
Is AbelZeta Pharma a public or private company?
AbelZeta Pharma is a private company.
What is the current stock price of AbelZeta Pharma?
AbelZeta Pharma is a private company with no public stock price. No recent secondary market data is available.
How much is AbelZeta Pharma worth (valuation)?
Valuation information for AbelZeta Pharma is not publicly available.
Can I buy AbelZeta Pharma stock?
AbelZeta Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was AbelZeta Pharma's last funding round?
AbelZeta Pharma's most recent funding round was Series A on September 30, 2021.
Who are the main investors in AbelZeta Pharma?
Key investors in AbelZeta Pharma include CICC Capital, HongShan, Yunfeng Capital.
Will AbelZeta Pharma IPO soon?
No public IPO plans have been announced for AbelZeta Pharma.
How can I track AbelZeta Pharma secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AbelZeta Pharma's secondary market activity and sign up for updates.